MEDIAN Technologies sealed its alliance agreement with Quintiles at the ASCO annual conference
The Sophia Antipolis-based medical imaging software developer finalised an agreement in Chicago before representatives of the biopharmaceutical industry.
MEDIAN Technologies, based in the Sophia Antipolis, announced its participation yesterday in the ASCO annual conference, the first world conference in oncology, which will take place from June 1 to 5 in Chicago, USA.
The occasion to formalise the operational launch of its alliance agreement with Quintiles, the first world leader in biopharmaceutical services, before representatives of the biopharmaceutical industry and the community of clinical investigators.
The alliance agreement between MEDIAN Technologies and Quintiles focuses on oncology; its purpose is to provide the biopharmaceutical industry and clinical investigators with new solutions for higher quality data, better productivity, increased visibility in go/no go decisions, and finally, for compiling stronger regulatory files.
“For the past three months we have been creating a highly efficient, integrated operational alliance to deliver what we believe is a truly differentiated medical imaging service to the biopharmaceutical industry” said Fredrik Brag, CEO of MEDIAN Technologies. “Working with Quintiles broadens the scope of clinical trials using our imaging technology to a global level, resulting in better outcomes for today’s patients.”
Today, the data taken from medical images are fundamental in the development and evaluation of new therapies against cancer. But, the inherent complexity of managing trials across multiple clinical sites introduces challenges, some of which threaten their clinical value. MEDIAN is changing the paradigm by proposing a new approach based on innovative technologies in order to find new solutions to more frequent problems in the interpretation and management of image data: the variability in data interpretation and a rising complexity of image workflows.
ASCO is thus the occasion for the MEDIAN representatives to present this approach through the results of the ‘Reliability of Imaging Biomarkers for Response Assessment in Advanced Lung Cancer: Influence of Expertise and Automation’.